Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study

被引:36
|
作者
Jaeger, Veronika K. [1 ]
Hoffman, Hal M. [2 ,3 ]
van der Poll, Tom [4 ,5 ]
Tilson, Hugh [6 ]
Seibert, Julia [7 ]
Speziale, Antonio [7 ]
Junge, Guido [7 ]
Franke, Kristina [8 ]
Vritzali, Eleni [7 ]
Hawkins, Philip N. [9 ]
Kuemmerle-Deschner, Jasmin [10 ]
Walker, Ulrich A. [1 ]
机构
[1] Univ Hosp Basel, Dept Rheumatol, Petersgraben 4, CH-4031 Basel, Switzerland
[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[3] Rady Childrens Hosp, Div Allergy & Immunol, San Diego, CA USA
[4] Univ Amsterdam, Div Infect Dis, Amsterdam, Netherlands
[5] Univ Amsterdam, Ctr Expt & Mol Med, Acad Med Ctr, Amsterdam, Netherlands
[6] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
[7] Novartis Pharma AG, Basel, Switzerland
[8] QuintilesIMS, Real World Insights, Res Triangle Pk, NC USA
[9] UCL, Natl Amyloidosis Ctr, London, England
[10] Univ Hosp Tuebingen, Dept Pediat, Div Pediat Rheumatol, Tubingen, Germany
关键词
cryopyrin-associated periodic syndromes; CAPS; vaccinations; safety; PNEUMOCOCCAL PNEUMONIA; INFLAMMASOME; PATHOGENESIS; VACCINE;
D O I
10.1093/rheumatology/kex185
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Pneumococcal, tetanus and influenza vaccinations are recommended for patients with cryopyrin- associated periodic syndromes (CAPS) when treated with immunosuppressive medication. The aim of this publication is to report the safety of pneumococcal and other vaccinations in CAPS patients. Methods. All CAPS patients followed in the beta-CONFIDENT (Clinical Outcomes and Safety Registry study of Ilaris patients) registry were analysed if they had received a vaccination. The b-CONFIDENT registry is a global, long-term, prospective, observational registry, capturing and monitoring patients treated with canakinumab. Results. Sixty-eight CAPS patients had received a total of 159 vaccine injections, 107 injections against influenza, 19 pneumococcal vaccinations, 12 against tetanus/diphtheria antigens and 21 other vaccinations. Fourteen per cent of injections had elicited at least one vaccine reaction. All five vaccine-related serious adverse events were associated with pneumococcal vaccination. Vaccine reactions were observed in 70% of pneumococcal vaccinations, compared with 7% in influenza and 17% in tetanus/diphtheria vaccinations. The odds ratios to react to the pneumococcal vaccines compared with influenza and tetanus/diphtheria vaccines were 31.0 (95% CI: 8, 119) and 10.8 (95% CI: 2, 74). Vaccine reactions after pneumococcal vaccinations were more severe and lasted significantly longer (up to 3 weeks) compared with other vaccinations. In two patients, pneumococcal vaccination also elicited symptoms consistent with systemic inflammation due to CAPS reactivation. Conclusion. Pneumococcal vaccines, unlike other vaccines, frequently trigger severe local and systemic inflammation in CAPS patients. Clinicians must balance potential benefits of pneumococcal immunization against safety concerns. The 13-valent pneumococcal conjugate vaccine might be favourable over the polysaccharide vaccine in CAPS patients.
引用
收藏
页码:1484 / 1491
页数:8
相关论文
共 50 条
  • [1] Cryopyrin-associated periodic syndromes
    Quartier, P.
    Rodrigues, F.
    Georgin-Lavialle, S.
    [J]. REVUE DE MEDECINE INTERNE, 2018, 39 (04): : 287 - 296
  • [2] CanakinumabIn Patients with Cryopyrin-Associated Periodic Syndromes
    Monique P. Curran
    [J]. BioDrugs, 2012, 26 (1) : 53 - 59
  • [3] Canakinumab In Patients with Cryopyrin-Associated Periodic Syndromes
    Curran, Monique P.
    [J]. BIODRUGS, 2012, 26 (01) : 53 - 59
  • [4] Cryopyrin-associated periodic syndromes and autoinflammation
    Shinkai, K.
    McCalmont, T. H.
    Leslie, K. S.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2008, 33 (01) : 1 - 9
  • [5] Canakinumab for the cryopyrin-associated periodic syndromes
    Savic, Sinisa
    McDermott, Michael F.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (10) : 529 - 530
  • [6] Canakinumab for the cryopyrin-associated periodic syndromes
    Sinisa Savic
    Michael F. McDermott
    [J]. Nature Reviews Rheumatology, 2009, 5 : 529 - 530
  • [7] Cryopyrin-associated Periodic Syndromes and the Eye
    Oberg, Thomas J.
    Vitale, Albert T.
    Hoffman, Robert O.
    Bohnsack, John F.
    Warner, Judith E.
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2013, 21 (04) : 306 - 309
  • [8] Anakinra desensitisation in patients with cryopyrin-associated periodic syndromes
    Ali, S. B.
    Le, T-T A.
    Kette, F.
    Hissaria, P.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (01) : 13 - 16
  • [9] Cryopyrin-associated periodic syndromes: background and therapeutics
    Kubota, Tetsuo
    Koike, Ryuji
    [J]. MODERN RHEUMATOLOGY, 2010, 20 (03) : 213 - 221
  • [10] Cryopyrin-Associated Periodic Syndromes Diagnosis and Management
    Miyamae, Takako
    [J]. PEDIATRIC DRUGS, 2012, 14 (02) : 109 - 117